RYTM Stock Analysis: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$114.17
3.76 (3.41%)
▲
5d:
+5.46%
30d:
+35.35%
90d:
+29.56%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
29d
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: RYTM is 14.7% above its trading range ($99.50). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: RYTM is 14.7% above its trading range ($99.50). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $114.17, which is considered extended relative to its 30-day fair value range of $84.58 to $99.50.
Technical Outlook: Technically, RYTM is showing sideways momentum. The price is approaching resistance at $114.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: RYTM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $139.47 (+22.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RYTM is showing sideways momentum. The price is approaching resistance at $114.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: RYTM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $139.47 (+22.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$84.58 -
$99.50
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
RYTM is technically overbought (RSI 80). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+14.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 22.2% below Wall St target ($139.47)
Trading Range Analysis
30-Day Trading Range
$84.58 -
$99.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$95.97
Resistance Level
$114.59
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-153.99
Wall Street Target
$139.47
(+22.2%)
Revenue Growth (YoY)
83.8%
Profit Margin
-93.3%
Share & Embed Analysis
Last updated: July 04, 2026 11:49 PM ET
Data refreshes hourly during market hours. Next update: 12:49 AM
Data refreshes hourly during market hours. Next update: 12:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Paul German
SELL
5614 shares
2026-03-04
Hunter C Smith
SELL
4385 shares
2026-02-19
Hunter C Smith
SELL
3569 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
